Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company

Corcept Therapeutics (NASDAQ: CORT ) recently shared that its Phase 3 ROSELLA trial met its primary goal, and the stock is up over 80% in trading on March 31, 2025. In our view, the results are very promising and may Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CORT over the next 72 hours. I wrote this art ...